Drug Trial Radar · NCT00414102
Subjective Efficacy of Ramelteon on Sleep in Adults With Chronic Insomnia.
Last checked: Nov 20, 2026Latest source record: Jun 28, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
552
Actual
Start
Oct 2006
Primary completion
Sep 2007
Study completion Sep 2007
Sponsor
- Lead sponsor
- TakedaTakeda (TAK)
- Sponsor type
- Industry
- First posted
- Dec 21, 2006
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 64 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the subjective treatment effects of ramelteon, once daily (QD), on sleep using a post sleep questionnaire-interactive voice response system in adults with chronic insomnia.
Conditions
- Chronic Insomnia
Interventions
RamelteonDrug
Ramelteon 8mg, tablets, orally, once nightly for up to 28 days.
PlaceboDrug
Ramelteon placebo-matching tablets, orally, once nightly for up to 28 days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Average subjective Sleep Latency from Day 15 to Day 21Time frame: Day 22
Locations
52 sites in 1 country. Site status is shown where the registry gives one.
Site not named
Phoenix, Arizona
Site not named
Tucson, Arizona
Site not named
Hot Springs, Arkansas
Site not named
Los Angeles Area, California
Site not named
San Diego, California
Site not named
Colorado Springs, Colorado
Site not named
Denver Area, Colorado
Site not named
Delray Beach, Florida
Site not named
Fort Myers, Florida
Site not named
Miami, Florida
Site not named
Naples, Florida
Site not named
Ocala, Florida
Site not named
Orlando, Florida
Site not named
Tampa, Florida
Site not named
Atlanta, Georgia
Site not named
Honolulu, Hawaii
Site not named
Boise, Idaho
Site not named
Chicago, Illinois
Site not named
Kansas City Area, Kansas
Site not named
Lexington, Kentucky
Site not named
Baton Rouge, Louisiana
Site not named
Auburn, Maine
Site not named
Baltimore Area, Maryland
Site not named
Washington D.C. Area, Maryland
Site not named
Hattiesburg, Mississippi
Site not named
Saint Louis Area, Missouri
Site not named
Albuquerque, New Mexico
Site not named
Long Island City, New York
Site not named
New York, New York
Site not named
Rochester, New York
Site not named
Staten Island, New York
Site not named
Charlotte, North Carolina
Site not named
Morganton, North Carolina
Site not named
Winston-Salem, North Carolina
Site not named
Akron, Ohio
Site not named
Cincinnati, Ohio
Site not named
Cleveland, Ohio
Site not named
Gallipolis, Ohio
Site not named
Oklahoma City, Oklahoma
Site not named
Portland Area, Oregon
Showing 40 of 52 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.